Novo Nordisk rises premarket on FDA boost, dividend payout
Novo Nordisk gained over 3% premarket after the FDA granted accelerated approval for Wegovy in treating MASH, a liver disease affecting 5% of US adults. The move follows a $70 billion market cap wipeout in July and a leadership shakeup. New CEO Maziar Doustdar pledged sharper execution, while investors also eyed a 7% higher interim dividend.